Drug intelligence / Profile preview

calcium carbonate + calcitriol

Development stage: Approved
Lead developer: UniOrange Group
Modality: Small Molecules
Administration: Oral

Overview

Shel D-CT is an oral fixed-dose combination of calcium carbonate and calcitriol (the active hormonal form of vitamin D3). It is formulated to treat and prevent calcium and vitamin D deficiencies, as well as manage bone disorders such as osteoporosis, osteomalacia, rickets, hypocalcemia, and renal osteodystrophy. Calcium carbonate serves as an essential mineral source to maintain bone density and skeletal structure. Calcitriol acts as a potent agonist of the vitamin D receptor (VDR), enhancing active calcium and phosphate absorption in the intestines and regulating bone mineralization. The combination is marketed in India by Uniorange Life Care.

Brand names: Shel D-CTShelcal-CT
Other names: calcium plus vitamin D

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on calcium carbonate + calcitriol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on calcium carbonate + calcitriol.

Explore the full profile